Neuroendocrine Tumors (NETs)
- Disease Education
- MOA Resources
- Clinical Trials
What is Radioligand Imaging and Therapy in Cancer?
[177Lu]Lu-DOTA-TATE Mechanism of Action
Explore the mechanism of action of targeted radioligand therapy (RLT) [177Lu]Lu-DOTA-TATE.
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.
Explore Clinical Trials
NETTER-2
A Phase III, multicenter, randomized, open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 2 and Grade 3 advanced GEP-NET
NeoRay
A Phase I/IIa, open-label, multicenter study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry, and antitumor activity of [177Lu]Lu-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)
NETTER-P
A Phase II, multicenter, open-label study to evaluate safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NET) and pheochromocytomas and paragangliomas (PPGL)
LysaKare PASS
A Phase IV, multicenter, open-label, post-authorization safety study to evaluate the effect of L-arginine HCl/L-lysine HCL infusion on serum potassium levels in GEP-NET patients eligible for [177Lu]Lu-DOTA-TATE treatment
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
[177Lu]Lu-DOTA-TATE
SSTR-targeted peptide receptor radionuclide therapy
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. MOA data are based on in vitro/in vivo data. Clinical benefit is unknown.